Track the peptide drug pipeline.

Real-time clinical trial data on GLP-1, dual-agonists, triple-agonists, and next-generation peptide therapeutics. Curated for investors, analysts, and researchers.

847 active trials 128 drugs tracked 41 indications Last sync: 2026-06-19 00:42 UTC
Phase
Indication
Company
Status

Pipeline — Obesity, T2DM, and Metabolic Indications

Showing 8 of 128 · Sorted by phase ↓ · Updated 2026-06-18
Drug ▼ Class Indication Phase Status Primary Completion Last Update NCT
RetatrutideEli Lilly · LY3437943 GLP-1 / GIP / glucagon tri-agonist Obesity Phase 3 Active 2026-12 2026-05-14 NCT05829020
CagriSemaNovo Nordisk · NN9487 GLP-1 / amylin combo Obesity Phase 3 Active 2026-12 2026-05-02 NCT05567796
OrforglipronEli Lilly · LY3502970 GLP-1 oral (non-peptide) Obesity Phase 3 Active 2027-02 2026-04-21 NCT05869903
SurvodutideBoehringer Ingelheim · BI 456906 GLP-1 / glucagon dual-agonist MASH Phase 3 Recruiting 2027-03 2026-05-08 NCT04881760
MazdutideInnovent · IBI362 GLP-1 / glucagon dual-agonist Obesity Phase 3 Active 2027-06 2026-05-30 NCT05607680
AmycretinNovo Nordisk · NN9487-2 GLP-1 / amylin (next-gen) Obesity Phase 1/2 Recruiting 2027-09 2026-06-03 NCT06131226
TirzepatideEli Lilly · LY3298176 (Zepbound / Mounjaro) GLP-1 / GIP dual-agonist T2DM / Obesity Approved Launched 2022-05 2026-05-22 NCT04184622
Semaglutide (oral)Novo Nordisk · Rybelsus GLP-1 oral peptide T2DM / Obesity Approved Launched 2021 2026-04-09 NCT03919929
RetatrutideEli Lilly · TRIUMPH-6 (HFpEF) GLP-1 / GIP / glucagon tri-agonist HFpEF + Obesity Phase 3 Recruiting 2027-08 2026-05-19 NCT06160816
SurvodutideBoehringer Ingelheim · SYNCHRONIZE-2 GLP-1 / glucagon dual-agonist Obesity Phase 3 Active 2027-11 2026-05-28 NCT06077864

Phase distribution

128 drugs · all metabolic indications
Phase 1
23
Phase 1/2
14
Phase 2
31
Phase 3
36
Approved
24

Top companies

By active programs
Eli Lilly LLY
Active programs14
Phase 3 trials8
Indications9
Retatrutide · Orforglipron · Tirzepatide · Mazdutide (CN rights) · LY3541104 · +9 more
Novo Nordisk NVO
Active programs11
Phase 3 trials6
Indications7
CagriSema · Amycretin · Semaglutide · NN9487-3 · NN9541 · +6 more
Innovent 1801.HK
Active programs6
Phase 3 trials2
Indications4
Mazdutide · IBI362 (T2DM) · IBI303 · +3 more
Boehringer Ingelheim private
Active programs4
Phase 3 trials2
Indications3
Survodutide · BI 456906 (MASH) · +2 more

Recent updates

View all updates →
2026-06-18
Phase 3 Retatrutide obesity Phase 3 read-out pushed from Q3 to Q4 2026; Lilly cites enrollment pace in TRIUMPH-2 sub-study. LLY −1.8% AH.
Lilly IR
2026-06-15
Enrollment CagriSema REDEFINE-2 enrolls 1,200 patients, hitting interim target two months ahead of schedule. Topline expected H1 2027.
ClinicalTrials.gov
2026-06-12
Approval Tirzepatide receives FDA label expansion for HFpEF in patients with obesity. SUMMIT subgroup data presented at ADA.
FDA / Lilly PR
2026-06-09
Initiation Amycretin Phase 2a obesity trial opens for enrollment in Denmark and US. Single ascending dose, 12-week endpoint.
Novo Nordisk
2026-06-04
Safety Survodutide MASH Phase 3 (LIVERAGE) DSMB lifts partial clinical hold after review of GI event signals; trial resumes enrollment.
BI IR

Indications being pursued

41 indications across 128 active programs
Obesity
62 programs · 24 Phase 3
Type 2 Diabetes
38 programs · 12 Phase 3
MASH / NASH
17 programs · 5 Phase 3
Obstructive Sleep Apnea
6 programs · 2 Phase 3
Chronic Kidney Disease
9 programs · 3 Phase 3
HFpEF (Heart Failure)
8 programs · 3 Phase 3
Alzheimer’s Disease
4 programs · 1 Phase 2
Cardiovascular Outcomes
11 programs · 4 Phase 3
Parkinson’s Disease
3 programs · 1 Phase 2
NAFLD
5 programs · 1 Phase 2
Polycystic Ovary Syndrome
4 programs · 1 Phase 2
Alcohol Use Disorder
2 programs · Phase 2

Methodology

Last review: 2026-06-15

Data is sourced from ClinicalTrials.gov, FDA/EMA approval databases, company filings (10-K, 10-Q, 20-F, 6-K), earnings call transcripts, and peer-reviewed publications (NEJM, JAMA, Lancet, Nature Med). Pipeline state is updated weekly; trial-level updates are pushed within 24 hours of material events.

  • Phase classification — based on the most advanced active trial for a drug-indication pair. "Approved" is assigned only after FDA/EMA action.
  • Status — Active = ongoing, Recruiting = enrolling, Completed = last visit done, Launched = commercial.
  • Primary completion date — per ClinicalTrials.gov primary completion field, not estimated readout.
  • Class — receptor agonism profile. Tri-agonist indicates three receptor targets (e.g., GGG = GLP-1/GIP/glucagon).
  • Coverage — peptide and peptide-class molecules (incl. oral non-peptide GLP-1R agonists such as orforglipron).